2. Search Result
Search Result
Results for "

permeability transition pore inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100852
    ER-000444793
    2 Publications Verification

    		 Mitochondrial Metabolism Cancer
    ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8?μM.
    ER-000444793
  • HY-112715
    ATP synthase inhibitor 1

    		ATP Synthase Cardiovascular Disease
    ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
    ATP synthase inhibitor 1
  • HY-131370B
    Intralipid 20%

    		Others Cancer
    Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response .
    Intralipid 20%
  • HY-131139A
    Ganglioside GD3 diammonium

    		Apoptosis Neurological Disease Cancer
    Ganglioside GD3 diammonium is an acidic glycosphingolipid. Ganglioside GD3 diammonium inhibits the proliferation of cancer cells, affects the opening of the mitochondrial permeability transition pore (PTPC), induces apoptosis and activates caspase family. Ganglioside GD3 diammonium can be used in research about cancer and neurodegenerative diseases .
    Ganglioside GD3 diammonium
  • HY-108984
    BBMP

    5-(Benzylsulfonyl)-4-bromo-2-methyl-3(2H)-pyridazinone

    		 Mitochondrial Metabolism Neurological Disease
    BBMP is a permeability transition pore (PTP) inhibitor. BBMP prevents Ca 2+-induced permeability transition and mitochondrial depolarization. BBMP possess potential for the neurodegenerative disorders research .
    BBMP
  • HY-119909
    GNX-865

    		Mitochondrial Metabolism Cardiovascular Disease
    GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo .
    GNX-865
  • HY-136804
    CypD-IN-29

    		Others Neurological Disease
    CypD-IN-29 (compound 29) is an inhibitor of the Alzheimer's disease target CypD (KD=88.2 nM). CypD is a mitochondrial-specific cyclophilin that can bind to β-amyloid protein in brain mitochondria and promote the formation of mitochondrial permeability transition pore (mPTP).
    CypD-IN-29
  • HY-131139
    Ganglioside GD3 disodium salt

    		Apoptosis Neurological Disease Cancer
    Ganglioside GD3 disodium salt is an acidic glycosphingolipid. Ganglioside GD3 disodium salt inhibits the proliferation of cancer cells, affects the opening of the mitochondrial permeability transition pore (PTPC), induces apoptosis and activates caspase family. Ganglioside GD3 disodium salt can be used in research about cancer and neurodegenerative diseases .
    Ganglioside GD3 disodium salt
  • HY-114898
    ML404

    		Others Cardiovascular Disease Neurological Disease
    ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke .
    ML404
  • HY-101999
    EM20-25

    		Bcl-2 Family Caspase Apoptosis Cancer
    EM20-25 is an inhibitor for Bcl-2, which interferes with the interaction between BCL-2 and BAX, activates caspase-9 and thus induces the apoptosis. EM20-25 affects the mitochondrial function, causes the open of permeability transition pore (PTP). EM20-25 enhances the sensitivity of cells to Staurosporine (HY-15141), and enhances the killing effect of BCL-2-expressing leukemia cells to Chlorambucil (HY-13593) and Fludarabine (HY-B0069) .
    EM20-25
  • HY-15763
    Erastin
    425+ Cited Publications

    		 VDAC Ferroptosis Disulfidptosis Cancer
    Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
    Erastin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: